Phosphodiesterase 4B is essential for T(H)2-cell function and development of airway hyperresponsiveness in allergic asthma.

[1]  B. Ferruà,et al.  Regulation of interleukin 2 synthesis by cAMP in human T cells. , 1987, Journal of immunology.

[2]  R. Coffman,et al.  Interleukin 4 causes isotype switching to IgE in T cell-stimulated clonal B cell cultures , 1988, The Journal of experimental medicine.

[3]  G. Kammer.  The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. , 1988, Immunology today.

[4]  M. Gougerot-Pocidalo,et al.  Differential regulation of IL 6, IL 1 A, IL 1β and TNFα production in LPS-stimulated human monocytes: Role of cyclic AMP , 1990 .

[5]  N. Turner,et al.  Characterization of guinea-pig eosinophil phosphodiesterase activity. Assessment of its involvement in regulating superoxide generation. , 1991, Biochemical pharmacology.

[6]  C. Deutsch,et al.  Cyclic AMP directly inhibits IL-2 receptor expression in human T cells: expression of both p55 and p75 subunits is affected. , 1991, Journal of immunology.

[7]  S. Døskeland,et al.  Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3',5'-cyclic adenosine monophosphate on cell replication in human T lymphocytes. , 1992, The Journal of biological chemistry.

[8]  S. Durham,et al.  Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. , 1992, The New England journal of medicine.

[9]  T. Torphy,et al.  Beta-adrenoceptors, cAMP and airway smooth muscle relaxation: challenges to the dogma. , 1994, Trends in pharmacological sciences.

[10]  L. Lichtenstein,et al.  IL-13 expression at the sites of allergen challenge in patients with asthma. , 1995, Journal of immunology.

[11]  J. Pène,et al.  Role of cyclic nucleotides and nitric oxide in blood mononuclear cell IgE production stimulated by IL-4. , 1995, Cytokine.

[12]  J. Nadel,et al.  Elevated intracellular cyclic AMP inhibits chemotaxis in human eosinophils. , 1995, Cellular signalling.

[13]  V. Lagente,et al.  Selective inhibition of phosphodiesterase type IV suppresses the chemotactic responsiveness of rat eosinophils in vitro. , 1996, European journal of pharmacology.

[14]  P. Foster,et al.  Interleukin 5 deficiency abolishes eosinophilia, airways hyperreactivity, and lung damage in a mouse asthma model , 1996, The Journal of experimental medicine.

[15]  R. Looney,et al.  Regulation of IgE and cytokine production by cAMP: implications for extrinsic asthma. , 1996, Clinical immunology and immunopathology.

[16]  J. Beleta,et al.  Inhibition of eotaxin‐mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram , 1997, British journal of pharmacology.

[17]  S. Christensen,et al.  Antiasthmatic activity of the second-generation phosphodiesterase 4 (PDE4) inhibitor SB 207499 (Ariflo) in the guinea pig. , 1998, The Journal of pharmacology and experimental therapeutics.

[18]  D B Corry,et al.  Requirement for IL-13 independently of IL-4 in experimental asthma. , 1998, Science.

[19]  D D Donaldson,et al.  Interleukin-13: central mediator of allergic asthma , 1998 .

[20]  M. Houslay,et al.  The multienzyme PDE4 cyclic adenosine monophosphate-specific phosphodiesterase family: intracellular targeting, regulation, and selective inhibition by compounds exerting anti-inflammatory and antidepressant actions. , 1998, Advances in pharmacology.

[21]  T. Torphy.  Phosphodiesterase isozymes: molecular targets for novel antiasthma agents. , 1998, American journal of respiratory and critical care medicine.

[22]  S. Christensen,et al.  SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions. , 1998, The Journal of pharmacology and experimental therapeutics.

[23]  W. P. Kuo,et al.  Impaired growth and fertility of cAMP-specific phosphodiesterase PDE4D-deficient mice. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  I. C. Almeida,et al.  Differential inhibitory mechanism of cyclic AMP on TNF‐α and IL‐12 synthesis by macrophages exposed to microbial stimuli , 1999, British journal of pharmacology.

[25]  R. Wange,et al.  Specific CD3 epsilon association of a phosphodiesterase 4B isoform determines its selective tyrosine phosphorylation after CD3 ligation. , 1999, Journal of immunology.

[26]  S. Jin,et al.  Absence of muscarinic cholinergic airway responses in mice deficient in the cyclic nucleotide phosphodiesterase PDE4D. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Gelfand,et al.  Interleukin (IL)-5 but not immunoglobulin E reconstitutes airway inflammation and airway hyperresponsiveness in IL-4-deficient mice. , 2000, American journal of respiratory cell and molecular biology.

[28]  M. Jordana,et al.  IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[29]  R. Pauwels,et al.  Specific Migratory Dendritic Cells Rapidly Transport Antigen from the Airways to the Thoracic Lymph Nodes , 2001, The Journal of experimental medicine.

[30]  D. Umetsu,et al.  Critical Role for IL-13 in the Development of Allergen-Induced Airway Hyperreactivity1 , 2001, The Journal of Immunology.

[31]  S. Yamamoto,et al.  Antiasthmatic effect of YM976, a novel PDE4 inhibitor, in guinea pigs. , 2001, Journal of Pharmacology and Experimental Therapeutics.

[32]  M. Mäkelä,et al.  Tumor Necrosis Factor- α Negatively Regulates Airway Hyperresponsiveness through γδ T Cells , 2001 .

[33]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[34]  D. Corry,et al.  Interleukins-4, -5, and -13: emerging therapeutic targets in allergic disease. , 2002, Pharmacology & therapeutics.

[35]  S. Jin,et al.  Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Madrenas,et al.  Regulation of T-Cell Activation by Phosphodiesterase 4B2 Requires Its Dynamic Redistribution during Immunological Synapse Formation , 2003, Molecular and Cellular Biology.

[37]  D. Umetsu,et al.  PDE4D plays a critical role in the control of airway smooth muscle contraction , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  Tomas Mustelin,et al.  Positive and negative regulation of T-cell activation through kinases and phosphatases. , 2003, The Biochemical journal.

[39]  S. Mackenzie,et al.  The effect of selective phosphodiesterase inhibitors, alone and in combination, on a murine model of allergic asthma , 2004, Respiratory research.

[40]  M. Pruniaux,et al.  Nonredundant Function of Phosphodiesterases 4D and 4B in Neutrophil Recruitment to the Site of Inflammation1 , 2004, The Journal of Immunology.

[41]  M. Zaccolo,et al.  TCR- and CD28-Mediated Recruitment of Phosphodiesterase 4 to Lipid Rafts Potentiates TCR Signaling1 , 2004, The Journal of Immunology.

[42]  S. Orkin,et al.  A Critical Role for Eosinophils in Allergic Airways Remodeling , 2004, Science.

[43]  Lauren Cohn,et al.  Asthma: mechanisms of disease persistence and progression. , 2004, Annual review of immunology.

[44]  S. Jin,et al.  Specific Role of Phosphodiesterase 4B in Lipopolysaccharide-Induced Signaling in Mouse Macrophages 1 , 2005, The Journal of Immunology.

[45]  B. Lipworth.  Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease , 2005, The Lancet.

[46]  S. Reiken,et al.  Phosphodiesterase 4D Deficiency in the Ryanodine-Receptor Complex Promotes Heart Failure and Arrhythmias , 2005, Cell.

[47]  M. Tsai,et al.  Mast Cell-Associated TNF Promotes Dendritic Cell Migration1 , 2006, The Journal of Immunology.

[48]  M. Conti,et al.  Differential Expression and Function of Phosphodiesterase 4 (PDE4) Subtypes in Human Primary CD4+ T Cells: Predominant Role of PDE4D1 , 2007, The Journal of Immunology.

[49]  E. Génin,et al.  Evidence for a Locus in 1p31 Region Specifically Linked to the Co-Morbidity of Asthma and Allergic Rhinitis in the EGEA Study , 2007, Human Heredity.

[50]  S. Galli,et al.  Mast cell-derived TNF contributes to airway hyperreactivity, inflammation, and TH2 cytokine production in an asthma model in mice. , 2007, The Journal of allergy and clinical immunology.

[51]  D. Spina,et al.  PDE4 inhibitors: current status , 2008, British journal of pharmacology.

[52]  F. Martinez,et al.  Roflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trials , 2009, The Lancet.

[53]  R. Tsujita,et al.  Discovery of selective PDE4B inhibitors. , 2009, Bioorganic & medicinal chemistry letters.